Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo

被引：22

作者：

Damm J.K. ^{[1
]}

Gordon S. ^{[1
]}

Ehinger M. ^{[2
]}

Jerkeman M. ^{[3
]}

Gullberg U. ^{[1
]}

Hultquist A. ^{[4
]}

Drott K. ^{[1
]}

机构：

[1] Department of Hematology and Transfusion Medicine, Lund University, Lund

[2] Department of Pathology, Skåne University Hospital, Lund

[3] Department of Oncology, Skåne University Hospital, Lund

[4] Stem Cell Center (SCC), Lund University, Lund

来源：

Experimental Hematology & Oncology | / 4卷 / 1期

关键词：

CD20; DLBCL; HDACi; Rituximab; Valproate; Valproic acid;

D O I：

10.1186/2162-3619-4-4

中图分类号：

学科分类号：

摘要：

Background: Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody rituximab (R-CHOP). The HDACi valproate, which has for long been utilized in anti-convulsive therapy, has been shown to sensitize to chemotherapy in vitro. Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma. Findings: Pretreatment with valproate at oral doses comparable to anti-convulsive therapy, resulted in upregulation of CD20 mRNA and CD20 protein on the cell surface as measured by qPCR and FACS analysis in lymphoma biopsies from three evaluated patients from the VALFRID study. Valproate-treatment corresponded to increased acetylation of Histone3Lysine9 (H3K9ac) in peripheral blood mononuclear cells (PBMCs), which were employed as surrogate tissue for valproate-related epigenetic modifications. Conclusions: Valproate treatment at pharmacologically relevant doses resulted in upregulation of CD20 in vivo, and also in expected epigenetic modifications. This suggests that pre-treatment with valproate or other HDACis before anti-CD20 therapy could be advantageous in CD20-low B-cell lymphomas. Further studies are warranted to evaluate this conclusion. © Damm et al.; licensee BioMed Central.

引用

共 17 条

[1]

McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., Et al., EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations, Nature, 492, pp. 108-112, (2012)

[2]

Pasqualucci L., Dominguez-Sola D., Chiarenza A., Fabbri G., Grunn A., Trifonov V., Et al., Inactivating mutations of acetyltransferase genes in B-cell lymphoma, Nature, 471, pp. 189-195, (2011)

[3]

Pasqualucci L., Trifonov V., Fabbri G., Ma J., Rossi D., Chiarenza A., Et al., Analysis of the coding genome of diffuse large B-cell lymphoma, Nat Genet, 43, pp. 830-837, (2011)

[4]

Advani R.H., Chen H., Habermann T.M., Morrison V.A., Weller E.A., Fisher R.I., Et al., Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI), Br J Haematol, 151, pp. 143-151, (2010)

[5]

Sugimoto T., Tomita A., Hiraga J., Shimada K., Kiyoi H., Kinoshita T., Et al., Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation, Biochem Biophys Res Commun, 390, pp. 48-53, (2009)

[6]

Tsai P.C., Hernandez-Ilizaliturri F.J., Bangia N., Olejniczak S.H., Czuczman M.S., Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma, Clin Cancer Res, 18, pp. 1039-1050, (2012)

[7]

Shimizu R., Kikuchi J., Wada T., Ozawa K., Kano Y., Furukawa Y., HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells, Leukemia, 24, pp. 1760-1768, (2010)

[8]

Chateauvieux S., Morceau F., Dicato M., Diederich M., Molecular and therapeutic potential and toxicity of valproic acid, J Biomed Biotechnol, (2010)

[9]

Ageberg M., Rydstrom K., Linden O., Linderoth J., Jerkeman M., Drott K., Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines, Exp Cell Res, 317, pp. 1179-1191, (2011)

[10]

Lund University Hospital: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (VALFRID)

← 1 2 →